SOHO 2024: Focus on MDS

Patrick DalyMyelodysplastic Syndromes | December 5, 2024
Tapotoclax was safe and may warrant consideration in combination with other therapies in MDS post-HMA failure.
Patrick DalyMyelodysplastic Syndromes | December 5, 2024
ESAs had a high rate of failure among patients with lower-risk MDS and often continued treatment despite failure.
Patrick DalyMyelodysplastic Syndromes | December 5, 2024
Oral azacitidine plus cedazuridine achieved pharmacokinetic equivalence to subcutaneous azacitidine in MDS and MPN.
Advertisement
Patrick DalyMyelodysplastic Syndromes | December 5, 2024
Retrospective analysis shows that AML treatment strategies are effective for patients with MDS or CMML with NPM1 mutations.
Julie GouldMyelodysplastic Syndromes | October 28, 2024
A novel multivariate model improved risk stratification in MDS compared with both the IPSS-R and IPSS-M.
Julie GouldMyelodysplastic Syndromes | October 28, 2024
The rate of abnormal cytogenetics among AA patients with MDS is comparable to or lower than the general population.
Advertisement
Julie GouldMyelodysplastic Syndromes | October 28, 2024
CDC database analysis suggests that MDS-related mortality has declined since 2011, though significant disparities remain.
Julie GouldMyelodysplastic Syndromes | October 28, 2024
The COMMANDS study compared the efficacy of luspatercept with epoetin alfa in ESA-naïve lower-risk MDS.
Andrew MorenoMyelodysplastic Syndromes | October 4, 2024
Patients who received oral HMAs had half the mean total of health care encounter days as those who received IV or SC HMAs.
Andrew MorenoMyelodysplastic Syndromes | October 4, 2024
A TP53 variant allele frequency threshold of 24% can inform MDS prognosis equally as well as TP53 allelic status.
Andrew MorenoMyelodysplastic Syndromes | October 4, 2024
The IPSS-M significantly improved MDS prognostic assessment, particularly for high-risk IPSS-R cases.
Andrew MorenoMyelodysplastic Syndromes | October 4, 2024
In patients with lower-risk MDS receiving luspatercept, electronic medical record alerts can help improve treatment dosing.
Patrick DalyMyelodysplastic Syndromes | September 26, 2024
COVID-19 infection was strongly correlated with severity, blast cell percentage, and degree of dysplasia in MDS.
Patrick DalyMyelodysplastic Syndromes | September 26, 2024
IDH1 inhibitor therapy significantly improved survival after HMA failure in patients with higher-risk MDS.
Patrick DalyMyelodysplastic Syndromes | September 26, 2024
Luspatercept yielded high rates of durable transfusion independence in heavily-pretreated, lower-risk MDS.
Patrick DalyMyelodysplastic Syndromes | September 26, 2024
Luspatercept yielded greater rates of improvement in cell lineages for patients with transfusion-dependent MDS.
Solly Chedid, MDMyelodysplastic Syndromes | October 24, 2024
COMMANDS is the first trial to perform a head-to-head comparison of luspatercept against an erythropoiesis-stimulating agent.
Andrew MorenoMyelodysplastic Syndromes | September 17, 2024
Enrolled patients had non-del(5q) relapsed or refractory disease and were ineligible for erythropoiesis-stimulating agents.
Andrew MorenoMyelodysplastic Syndromes | September 13, 2024
A retrospective study's regression analysis confirmed survival effect of cytarabine-based regimens and allogeneic HSCT.
Andrew MorenoMyelodysplastic Syndromes | September 13, 2024
Inherited thrombocytopenia is associated with risk for myelodysplastic syndromes and malignancies.
Advertisement
Advertisement